REG - Oxford Biomedica PLC - Result of AGM

Oxford BioMedicaAnnouncement

23/06/2023 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230623:nRSW8009Da&default-theme=true

RNS Number : 8009D  Oxford Biomedica PLC  23 June 2023

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 23 June 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a quality and innovation-led viral vector CDMO, announces
today that all resolutions proposed were duly passed at its Annual General
Meeting (AGM), held at 3pm on 23 June 2023 in Oxford. As proposed in the
Notice of AGM, all resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by
visiting the Company's website at www.oxb.com (http://www.oxb.com)

 

Copies of the document setting out the above resolutions passed at the 2023
AGM have been submitted to the National Storage Mechanism and will shortly be
available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

On the Record Date (21 June 2023) there were 96,521,209 ordinary shares of 50
pence each in issue, each carrying one vote per share.

 

                                                                                                                                                                                                                Result

                                                                                      Votes                                                              Votes                         Votes       Total

                                                                                      For (incl. votes at the Chairman's discretion)                     Against     % of votes cast   Withheld*   votes cast

      Resolution                                                                                                                       % of votes cast

      Ordinary resolutions

 1    To receive the Company's Accounts, the Reports of the Directors and Auditor     73,060,750                                       100.00%           629         0.00%             146,857     73,061,379   PASS

    and the Strategic Report for the year ended 31 December 2022.

 2    To receive the Directors' Remuneration Report and the Report of the Auditor on  51,080,127                                       79.93%            12,826,613  20.07%            9,301,496   63,906,740   PASS

    the Remuneration Report for the year ended 31 December 2022.

 3    To appoint Dr. Frank Mathias as a Director.                                     73,062,102                                       99.81%            137,244     0.19%             8,890       73,199,346   PASS

 4    To appoint Leone Patterson as a Director.                                       72,892,590                                       99.58%            307,356     0.42%             8,290       73,199,946   PASS

 5    To reappoint Dr. Roch Doliveux as a Director.                                   67,536,075                                       92.26%            5,662,468   7.74%             9,693       73,198,543   PASS

 6    To reappoint Professor Dame Kay Davies as a Director.                           66,057,059                                       90.24%            7,141,705   9.76%             9,472       73,198,764   PASS
 7    To reappoint Stuart Paynter as a Director.                                      72,551,391                                       99.11%            649,338     0.89%             7,507       73,200,729   PASS

 8    To reappoint Stuart Henderson as a Director.                                    66,051,339                                       90.25%            7,139,682   9.75%             17,215      73,191,021   PASS

 9    To reappoint Dr. Heather Preston as a Director                                  64,485,621                                       88.10%            8,713,178   11.90%            9,437       73,198,799   PASS

 10   To reappoint Robert Ghenchev as a Director.                                     73,059,336                                       99.81%            140,259     0.19%             8,641       73,199,595   PASS

 11   To reappoint Dr. Michael Hayden as a Director.                                  67,826,937                                       92.66%            5,371,827   7.34%             9,472       73,198,764   PASS

 12   To reappoint Catherine Moukheibir as a Director.                                68,240,515                                       93.22%            4,959,431   6.78%             8,290       73,199,946   PASS

 13   To reappoint Namrata P. Patel as a Director.                                    73,140,356                                       99.92%            59,590      0.08%             8,290       73,199,946   PASS

 14   To appoint PriceWaterhouseCoopers LLP as auditor.                               73,193,707                                       99.99%            7,290       0.01%             7,239       73,200,997   PASS

 15   To authorise the Directors to agree the remuneration of the auditor.            73,195,908                                       99.99%            4,776       0.01%             7,552       73,200,684   PASS

 16   To authorise the Directors to allot shares.                                     70,498,713                                       96.31%            2,702,643   3.69%             6,880       73,201,356   PASS

      Special resolutions
 17   To authorise the Directors to disapply pre-emption rights.                      72,202,544                                       98.64%            996,404     1.36%             9,288       73,198,948   PASS

 18   To authorise the Directors to further disapply pre-emption rights for           70,474,362                                       96.28%            2,721,812   3.72%             12,062      73,196,174   PASS

    acquisitions and specified capital investments.

 19   To permit the Directors to convene general meetings (other than annual general  71,049,162                                       97.06%            2,150,941   2.94%             8,133       73,200,103   PASS

    meetings) on not less than 14 days' notice.

 

* A vote withheld is not a vote in law and is not counted towards votes cast
in respect of a resolution.

 

In addition, further to the announcement by the Company in January, Dr.
Siyamak Rasty has stepped down from the Company's Board of Directors with
effect from the conclusion of today's AGM.

 

The Board recognises that, whilst resolution 2 was passed with a clear
majority at almost 80%, there was also a significant vote against this
resolution. The Board will seek to engage with those shareholders who voted
against this resolution and it is anticipated that a revised remuneration
policy will be presented to shareholders for their approval at the Company's
AGM in 2024. In accordance with the UK Corporate Governance Code, an update on
the views received from shareholders and details of any further actions taken
by the Company will be published no later than 23 December 2023 by way of
Stock Exchange Announcement. A summary will also be published in the 2023
Annual Report and Accounts.

 

 

 

-Ends-

 

 

 Enquiries:

 Oxford Biomedica plc:

 Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488/ E: ir@oxb.com

 Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
 ir@oxb.com

 Consilium Strategic Communications:

 T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , www.oxbsolutions.com (https://oxbsolutions.com/) ,
and follow us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/)
, Twitter (https://twitter.com/OxfordBioMedica) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSESFMDEDSEDM